AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Resmed DRC

33.610

+0.5701.73%

Volume:920.98K

Turnover:30.78M

Market Cap:4.93B

PE:26.14

High:33.610

Open:33.100

Low:33.100

Close:33.040

Loading ...

Overview Company News Filings

Press Release: Resmed Names Salli Schwartz as Chief Investor Relations Officer

ResMed Is Maintained at Overweight by Keybanc

Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline

The easy way to build significant wealth with ASX shares

What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings

ResMed Inc. Stock Falls Wednesday, Still Outperforms Market

ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth

How to build a winning $250,000 ASX share portfolio starting from zero

3 of the best ASX 200 healthcare shares to bring your portfolio to life

5 top ASX 200 stocks that brokers rate as buys after the market selloff

CSL, Resmed Are Morgan Stanley's Australia Healthcare Picks in the Tariff Era -- Market Talk

Morgan Stanley’s top-ranked ASX healthcare picks for right now

How I'd invest in ASX 200 shares if I wanted to sleep well during market volatility

ResMed Bull Braces for Possible Short-Lived Selloff -- Market Talk

What I'd buy if I wanted to turn $10,000 into $100,000 with ASX shares

3 ASX 200 stocks I'd buy and hold for the next 10 years

“We’re buying”: Emma Fisher spots a rare chance to upgrade the portfolio

ResMed Inc. Stock Falls Thursday, Still Outperforms Market

Why I'm taking a closer look at ResMed shares

The Fallen: Stocks hitting 52-week lows (and what investors should do)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RMD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":33.61,"timestamp":1744870320000,"preClose":33.04,"halted":0,"volume":920984,"delay":0,"nameEN":"Resmed DRC","floatShares":145682198,"shares":146618814,"eps":1.2859480944587327,"marketStatus":"Not Yet Opened","change":0.57,"latestTime":"04-17 16:12:00 AEST","open":33.1,"high":33.61,"low":33.1,"amount":30777256,"amplitude":0.015436,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.2859480944587327,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"adrRate":1,"exchange":"ASX","adjPreClose":33.04,"dividendRate":0.009149,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.5319607698766091,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145682198,"roa":"13.89%","roe":"25.65%","lyrEps":0.974203,"volumeRatio":0.5319607698766091,"shares":146618814,"dividePrice":0.307069,"high":33.61,"amplitude":0.015436,"preClose":33.04,"low":33.1,"week52Low":26.946,"pbRate":"0.60","psRate":"0.64","week52High":40.661,"institutionHeld":0,"latestPrice":33.61,"eps":1.2859480944587327,"divideRate":0.009149,"volume":920984,"delay":0,"ttmEps":1.2859480944587327,"open":33.1,"prevYearClose":36.689,"prevWeekClose":33.61,"prevMonthClose":34.96,"prevQuarterClose":34.96,"fiveDayClose":34.83,"twentyDayClose":35.26,"sixtyDayClose":39.413},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529355883","title":"Press Release: Resmed Names Salli Schwartz as Chief Investor Relations Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529355883","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529355883?lang=en_us&edition=fundamental","pubTime":"2025-04-22 05:00","pubTimestamp":1745269200,"startTime":"0","endTime":"0","summary":"Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she led the company's investor engagement strategy, representing the company's response to shareholders' perspectives on corporate strategy, capital allocation, and financial performance. She was also a member of Illumina's Corporate Social Responsibility Executive Steering Committee and its Transformation Office.Resmed  creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4082","LU2008162690.USD","BK7007","RMD.AU","BK4585","LU0170899867.USD","RMD","BK4588","LU2177674079.SGD","BK4567","BK7501","BK4504"],"gpt_icon":0},{"id":"2529389876","title":"ResMed Is Maintained at Overweight by Keybanc","url":"https://stock-news.laohu8.com/highlight/detail?id=2529389876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529389876?lang=en_us&edition=fundamental","pubTime":"2025-04-21 23:12","pubTimestamp":1745248320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 11:12 ET (15:12 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD.AU","RMD"],"gpt_icon":0},{"id":"2529438973","title":"Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2529438973","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529438973?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:00","pubTimestamp":1745244020,"startTime":"0","endTime":"0","summary":"The market expects InMode  to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 28. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.This maker of cosmetic surgery devices is expected to post quarterly earnings of $0.33 per share in its upcoming report, which represents a year-over-year change of -26.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-preview-inmode-inmd-q1-140020782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","RMD","INMD"],"gpt_icon":0},{"id":"2528102564","title":"The easy way to build significant wealth with ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2528102564","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528102564?lang=en_us&edition=fundamental","pubTime":"2025-04-19 05:12","pubTimestamp":1745010720,"startTime":"0","endTime":"0","summary":"A few quality ASX shares, like ResMed Inc  or Lovisa Holdings Ltd , combined with some global exposure via ASX ETFs like iShares S&P 500 ETF  or Betashares Global Quality Leaders ETF , could give you a diversified, growth-focused portfolio that does most of the work for you. It most probably won't double overnight. But it will grow. And in 10 or 20 years, you might just look back and realise that your boring investments were the smartest decisions you ever made.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/19/the-easy-way-to-build-significant-wealth-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["GMG.AU","BK7128","BK7099","BK7155","BK7503","QLTY.AU","IVV.AU","RMD.AU","TNE.AU","BK7501","BRN.AU","LOV.AU","BK7007","BK7510","BK7016"],"gpt_icon":1},{"id":"2528449767","title":"What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2528449767","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528449767?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:15","pubTimestamp":1744895722,"startTime":"0","endTime":"0","summary":"Wall Street analysts forecast that ResMed  will report quarterly earnings of $2.36 per share in its upcoming release, pointing to a year-over-year increase of 10.8%. It is anticipated that revenues will amount to $1.28 billion, exhibiting an increase of 7.3% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.Analysts expect 'Combined Europe, Asia, and other markets- Total' to come in at $3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analyst-projections-key-metrics-reveal-131522137.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2528420308","title":"ResMed Inc. Stock Falls Wednesday, Still Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2528420308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528420308?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:58","pubTimestamp":1744837080,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  shed 1.16% to $211.49 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 2.24% to 5,275.70 and Dow Jones Industrial Average  falling 1.73% to 39,669.39.This was the stock's second consecutive day of losses.ResMed Inc. closed 19.60% below its 52-week high of $263.05, which the company reached on January 30th.Trading volume  remained 126,305 below its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 16, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2528244912","title":"ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2528244912","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528244912?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:00","pubTimestamp":1744812056,"startTime":"0","endTime":"0","summary":"Wall Street expects a year-over-year increase in earnings on higher revenues when ResMed  reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 23. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.This maker of medical products for respiratory disorders is expected to post quarterly earnings of $2.36 per share in its upcoming report, which represents a year-over-year change of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resmed-rmd-reports-next-week-140056809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","RMD"],"gpt_icon":1},{"id":"2527765204","title":"How to build a winning $250,000 ASX share portfolio starting from zero","url":"https://stock-news.laohu8.com/highlight/detail?id=2527765204","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527765204?lang=en_us&edition=fundamental","pubTime":"2025-04-16 05:07","pubTimestamp":1744751220,"startTime":"0","endTime":"0","summary":"Building a $250,000 ASX share portfolio from scratch might seem like a big challenge, but with patience, discipline, and the right strategy, it is entirely possible. The key is to start investing earl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/16/how-to-build-a-winning-250000-asx-share-portfolio-starting-from-zero/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7007","BK7503","BK7099","BK7016","RMD.AU","BK7510","TNE.AU","VAS.AU","GMG.AU","BK7501","BK7155","NDQ.AU"],"gpt_icon":0},{"id":"2527447668","title":"3 of the best ASX 200 healthcare shares to bring your portfolio to life","url":"https://stock-news.laohu8.com/highlight/detail?id=2527447668","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527447668?lang=en_us&edition=fundamental","pubTime":"2025-04-16 02:00","pubTimestamp":1744740000,"startTime":"0","endTime":"0","summary":"If your portfolio needs a health check, then the healthcare sector could be just what the doctor ordered. ASX 200 healthcare shares have a history of delivering strong, long-term returns thanks to con","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/16/3-of-the-best-asx-200-healthcare-shares-to-bring-your-portfolio-to-life/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2471134523.USD","LU2471134952.CNY","LU2471134796.USD","LU1868836914.USD","BK7508","BK4552","IE0002270589.USD","BK7067","IE00BFXG1179.USD","IE0004091025.USD","RMD.AU","LU0048573561.USD","LU2237443622.USD","LU2750360997.AUD","LU2237443978.SGD","BK4127","BK4516","BK7501","PME.AU","BK7094","LU1791807156.HKD","LU1868836757.USD","LU2750360641.GBP","LU1868837136.USD","LU0742534661.SGD","BK7007","LU2471134879.HKD","BK4550","LU0061475181.USD","BK7511","LU2237443549.SGD","IE00B19Z3581.USD","LU2237443895.HKD","CSL.AU","IE00B19Z3B42.SGD","BK4585","LU1868836591.USD","LU1868837300.USD","BK4533","LU2237443465.HKD","IE0034235188.USD","LU2237438978.USD","BK4504","LU0251142724.SGD","BK4588","LU0106831901.USD","IE00BSNM7G36.USD","LU1668664300.SGD","IE0004086264.USD","LU2237443382.USD"],"gpt_icon":0},{"id":"2527448763","title":"5 top ASX 200 stocks that brokers rate as buys after the market selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=2527448763","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527448763?lang=en_us&edition=fundamental","pubTime":"2025-04-15 15:10","pubTimestamp":1744701034,"startTime":"0","endTime":"0","summary":"If you are on the lookout for some investment ideas, then it could be worth checking out what analysts saying. Listed below are five ASX 200 stocks that leading brokers currently rate as buy. Here's w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/15/5-top-asx-200-stocks-that-brokers-rate-as-buys-after-the-market-selloff/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7044","JHX.AU","BK7511","RMD.AU","BK7007","TLX.AU","BK7503","BK7016","XRO.AU","BK7067","BK7501","BK7046","MQG.AU","WTC.AU"],"gpt_icon":1},{"id":"2527481820","title":"CSL, Resmed Are Morgan Stanley's Australia Healthcare Picks in the Tariff Era -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527481820","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527481820?lang=en_us&edition=fundamental","pubTime":"2025-04-15 11:51","pubTimestamp":1744689060,"startTime":"0","endTime":"0","summary":"0351 GMT - Biopharmaceutical company CSL and medical equipment firm Resmed have the best combination of attractive valuation and low tariff impact among Australian healthcare stocks, suggests Morgan Stanley equity analyst David L. Bailey. He estimates that CSL would need to raise prices by 1% and Resmed would need to raise prices by 2%-3% to offset the earnings impact from tariffs. But given their solid earnings per share growth, low earnings risk and valuation appeal, he says these companies are the \"most favorably positioned\" among peers. One word of caution--pharmaceuticals are currently excluded from reciprocal tariffs, but Trump has signaled he wants to put tariffs on that sector soon, which could impact CSL. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","LU0314104364.USD","LU0971096721.USD","LU1720051017.SGD","BK7508","LU2023251221.USD","LU1668664300.SGD","BK4548","RMD","LU1169590202.USD","BK4567","SGXZ23171101.USD","LU1989772840.SGD","LU0795875086.SGD","CSL","LU2347655156.SGD","LU1548497426.USD","LU1363072403.SGD","LU1732800096.USD","BK4137","BK4581","HCSG","LU0795875169.SGD","BK4534","BK4588","LU2271345857.HKD","CSL.AU","BK4127","BK7511","BK7501","LU0225283273.USD","LU2089284900.SGD","LU0158827781.USD","LU0320765646.SGD","BK4516","LU1074936037.SGD","LU0912757837.SGD","RMD.AU","LU1720051108.HKD","LU0170899867.USD","LU2089283258.USD","MS","LU1162221912.USD","LU2177674079.SGD","LU0158827948.USD","LU0728928796.USD","BK4086","BK4082","LU0098860793.USD","SG9999004303.SGD"],"gpt_icon":1},{"id":"2527107074","title":"Morgan Stanley’s top-ranked ASX healthcare picks for right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2527107074","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527107074?lang=en_us&edition=fundamental","pubTime":"2025-04-15 10:46","pubTimestamp":1744685174,"startTime":"0","endTime":"0","summary":"Despite the latest noises out of the White House promising some tariff respite, Trump’s ongoing trade war remains the big spectre looming over markets.According to research from Morgan Stanley, one sector that could weather the storm is healthcare, especially if the worst were to happen and we entered a period of stagflation or even recession.Here are its two big-name stock picks and the reasons it thinks the sector is well-positioned right now.While pharmaceuticals are currently exempt from US tariffs, Trump hinted that an announcement on specific pharma tariffs could be expected “soon”.Regardless, Morgan Stanley believes leading ASX health stocks should be able to offset any tariff impact through minimal price increases.Using the GFC as an instructive case study, Morgan Stanley reviewed the performance of the healthcare industry against the ASX 200during that time in case we entered a similar period of lower growth, higher inflation and more unemployment.According to Morgan Stanley's","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/morgan-stanley-s-top-ranked-asx-healthcare-picks-for-right-now","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/morgan-stanley-s-top-ranked-asx-healthcare-picks-for-right-now","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU2347655156.SGD","LU2133065610.SGD","LU1363072403.SGD","LU1989772923.USD","LU0098860793.USD","BK7007","LU2357305700.SGD","MS","LU0006306889.USD","LU0106831901.USD","LU0225283273.USD","LU0795875086.SGD","BK4504","BK7508","LU2271345857.HKD","LU0912757837.SGD","BK7067","IE00BKVL7J92.USD","LU1720051108.HKD","LU0971096721.USD","LU0314104364.USD","BK4581","CSL.AU","RMD.AU","BK4516","BK7501","BK4585","LU0795875169.SGD","LU2028103732.USD","LU0158827948.USD","LU1720051017.SGD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU1732800096.USD","LU2089284900.SGD","LU0106261372.USD","BK7511","LU0158827781.USD","LU1668664300.SGD","BK4588","LU2023251221.USD","LU2111349929.HKD","LU2089283258.USD","LU1989772840.SGD","LU1162221912.USD","LU0320765646.SGD","BK4127","LU1732799900.SGD","LU0267386448.USD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2527713444","title":"How I'd invest in ASX 200 shares if I wanted to sleep well during market volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2527713444","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527713444?lang=en_us&edition=fundamental","pubTime":"2025-04-14 17:33","pubTimestamp":1744623232,"startTime":"0","endTime":"0","summary":"Let's face it — the share market can be a stressful place when prices are falling, headlines are screaming, and your portfolio is flashing red. But the truth is, volatility is part of the investment r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/how-id-invest-in-asx-200-shares-if-i-wanted-to-sleep-well-during-market-volatility/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7082","BK7099","IVV.AU","BK7067","BK4585","COL.AU","TLS.AU","BK4588","BK7510","BK7155","NDQ.AU","BK7501","BK7040","BK7007","QLTY.AU","RMD.AU","GMG.AU","BK7511","BK4550","BK7508","BK7042","CSL.AU","FDN"],"gpt_icon":0},{"id":"2527382915","title":"ResMed Bull Braces for Possible Short-Lived Selloff -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527382915","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527382915?lang=en_us&edition=fundamental","pubTime":"2025-04-14 07:21","pubTimestamp":1744586460,"startTime":"0","endTime":"0","summary":"2321 GMT -- ResMed's bull at Citi is bracing for the possibility of a short-lived share sell-off when trial results from Eli Lilly's Orforglipron weight-loss drug are announced. Analyst Mathieu Chevrier keeps a buy rating on the breathing-tech provider, but opens a 90-day downside catalyst watch on the release of Orforglipron's phase 3 readout, which is expected some time in the June quarter. Chevrier reminds clients in a note that ResMed's share price has reacted negatively to GLP-1 news in the past, but he doesn't expect any selloff to be long-lasting. Citi has a A$44.00 target price on the stock, which is at A$34.21 ahead of the open. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","LU2008162690.USD","LU2177674079.SGD","RMD.AU","BK7007","RMD","BK4082","BK4588","BK4567","BK7501","BK4548","BK4504","BK4585"],"gpt_icon":1},{"id":"2527329935","title":"What I'd buy if I wanted to turn $10,000 into $100,000 with ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2527329935","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527329935?lang=en_us&edition=fundamental","pubTime":"2025-04-13 06:06","pubTimestamp":1744495560,"startTime":"0","endTime":"0","summary":"You'll probably be waiting a long time. The better approach is to start with what you have, invest in quality, and stay consistent. This is where dollar cost averaging can help — buying regularly smooths out volatility and removes the guesswork. The real secret isn't predicting the next breakout winner — it is being early, being patient, and staying disciplined. What would I buy?Personally, I'd be looking for long-term compounders with real staying power. Businesses like ResMed Inc , WiseTech Global Ltd , and Xero Ltd , or an ETF like BetaShares Nasdaq 100 ETF  or VanEck Morningstar Wide Moat ETF  — names that don't just grow, but compound earnings over time. They won't all shoot the lights out overnight. But give them a decade or more, and they could do some serious heavy lifting. Foolish takeaway Growing $10,000 into $100,000 isn't about luck. It is about owning great businesses, staying invested, and letting time do what time does best. It might take years. It will definitely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/13/what-id-buy-if-i-wanted-to-turn-10000-into-100000-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7016","NDQ.AU","RMD.AU","BK7007","WTC.AU","BK7503","BK4585","MOAT.AU","XRO.AU","BK7501","BK4588","BK4550","FDN"],"gpt_icon":0},{"id":"2526629371","title":"3 ASX 200 stocks I'd buy and hold for the next 10 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2526629371","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526629371?lang=en_us&edition=fundamental","pubTime":"2025-04-12 07:04","pubTimestamp":1744412640,"startTime":"0","endTime":"0","summary":"There's something powerful about backing a great business and simply holding on. Not for six months. Not until the next earnings update. But for a full decade — riding the waves, ignoring the noise, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/12/3-asx-200-stocks-id-buy-and-hold-for-the-next-10-years/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7007","LU1791807156.HKD","LU0061475181.USD","BK7016","LU1668664300.SGD","BK4533","RMD.AU","BK4552","LU1868837136.USD","LU2237438978.USD","WTC.AU","LU2471134952.CNY","BK4550","IE0004086264.USD","IE00B19Z3B42.SGD","BK4588","LU2237443465.HKD","LU0048573561.USD","IE0004091025.USD","LIF","LU0742534661.SGD","LU1868836757.USD","BK4585","LU2237443978.SGD","LU0251131958.USD","LU2471134523.USD","IE0034235188.USD","360.AU","LU2471134879.HKD","BK4127","IE00BSNM7G36.USD","LU0096364046.USD","BK7503","LU2237443622.USD","LU2237443895.HKD","LU1868837300.USD","BK4023","LU0251142724.SGD","LU2750360997.AUD","BK7501","LU2750360641.GBP","BK4613","IE00BFXG1179.USD","LU1868836914.USD","IE00B19Z3581.USD","LU1868836591.USD","LU0106831901.USD","LU2237443549.SGD","BK4504","IE0002270589.USD"],"gpt_icon":0},{"id":"2526050775","title":"“We’re buying”: Emma Fisher spots a rare chance to upgrade the portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2526050775","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526050775?lang=en_us&edition=fundamental","pubTime":"2025-04-11 13:30","pubTimestamp":1744349406,"startTime":"0","endTime":"0","summary":"Note: This podcast was recorded on the 9th of April 2025. Monday the 7th of April 2025 is a day few Aussie investors will forget, as the ASX 200 opened more than 6% lower on fears of escalating trade wars. The drop followed a sharp fall on US markets, capping what was the worst two-day period since March 2020.The moves took US stocks into bear market territory, leaving investors asking the question: “How low can this go?”For Emma Fisher, Deputy Head of Equities at Airlie Funds Management, it was a phone call from her mum that delivered a ‘soft signal’ that the worst of the selling may be behind us.Fisher, a self-confessed optimist, has been making the case for some time that equities were expensive and susceptible to a drawdown. Earnings and dividends on the ASX have been flat for the past two years, with equity returns driven largely by multiple expansion - often used as a proxy for investor exuberance.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/we-re-buying-emma-fisher-spots-a-rare-chance-to-upgrade-the-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/we-re-buying-emma-fisher-spots-a-rare-chance-to-upgrade-the-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["AASF.AU","ALL.AU","BK7103","SIG.AU","BK7501","BK7001","XKO.AU","XAO.AU","XJO.AU","JBH.AU","BK7007","BK7078","RMD.AU"],"gpt_icon":0},{"id":"2526544083","title":"ResMed Inc. Stock Falls Thursday, Still Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2526544083","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526544083?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:56","pubTimestamp":1744318560,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  slipped 2.72% to $210.55 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 3.46% to 5,268.05 and Dow Jones Industrial Average  falling 2.50% to 39,593.66.ResMed Inc. closed 19.96% below its 52-week high of $263.05, which the company achieved on January 30th.Trading volume  remained 33,424 below its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 10, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2526304027","title":"Why I'm taking a closer look at ResMed shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2526304027","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526304027?lang=en_us&edition=fundamental","pubTime":"2025-04-10 12:21","pubTimestamp":1744258896,"startTime":"0","endTime":"0","summary":"By most accounts, ResMed shares look to be squarely in the buy zone. According to broker Macquarie, ResMed is sufficiently positioned to withstand the brunt of President Trump's tariff fallout.  The broker notes that Resmed will be cushioned from the tariff blows because a significant portion of the company's manufacturing is conducted in the United States. Goldman Sachs also sees potential in the ResMed share price at its current valuation. The broker has a price target of $49 on ResMed shares. That represents a potential upside of 40%. As such, ResMed sits high up on my watch list.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/10/why-im-taking-a-closer-look-at-resmed-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4504","BK7501","LU0170899867.USD","BK4548","RMD","RMD.AU","BK4567","LU2177674079.SGD","BK4588","BK7007","LU2008162690.USD","BK4585","BK4082"],"gpt_icon":1},{"id":"2526364374","title":"The Fallen: Stocks hitting 52-week lows (and what investors should do)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526364374","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526364374?lang=en_us&edition=fundamental","pubTime":"2025-04-10 10:48","pubTimestamp":1744253281,"startTime":"0","endTime":"0","summary":"Earlier this week, I covered The Outlaws – stocks hitting 52-week highs despite the market sinking.The Outlaw Stocks: The ASX names defying the sell-off and hitting 52-week highs. Unlike in 2022, when almost every asset class fell in lockstep, this year we’ve seen defensives and fixed income ETFs do what they’re meant to do: offer ballast in a storm.Now, let's flip the script and look at the stocks and ETFs which hit 52-week lows before today's bigger-than-Ben-Hur rally. We'll call them:The Fallen.To be sure, these aren’t necessarily all bad businesses. As fund managers like Emanuel Datt, Adam Dawes, and Nick Peros have pointed out, a stock hitting a 52-week low isn’t always a red flag.It's a potential opportunity to pick up quality at a discount.Due to the sheer number of names hitting 52-week low, we’ve  focused this wire on two key ASX sectors – resources and financials – with expert insights to help investors make sense of the wreckage.You can download the full list below or use th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-fallen-stocks-hitting-52-week-lows-and-what-investors-should-do","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-fallen-stocks-hitting-52-week-lows-and-what-investors-should-do","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["RMD","BK7507","LU2237443978.SGD","LU2471134879.HKD","LU2471134796.USD","LU2028103732.USD","NXL","BK7508","LU0795875169.SGD","LU2008162690.USD","LU2237443549.SGD","REA.AU","RIO.AU","LU2023251221.USD","LU2089284900.SGD","LU2471134523.USD","LU1548497426.USD","LU1732800096.USD","BK4516","BK4550","LU2089283258.USD","LU0795875086.SGD","RMD.AU","BK4127","BK4552","PNI.AU","BHP.AU","XRO.AU","BK7002","LU0225283273.USD","GQG.AU","LU1868837136.USD","LU0158827948.USD","MIN.AU","LU0170899867.USD","CSL.AU","NDQ.AU","NXL.AU","LU0314104364.USD","LU2237438978.USD","LU1162221912.USD","MFG.AU","IE00B19Z3B42.SGD","LU0912757837.SGD","BK4585","TNE.AU","LU0742534661.SGD","MQG.AU","LU0251131958.USD","BK7016"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"},{"date":"2024-11-06","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-11-07","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730811600000,"payDate":"2024-12-12"},{"date":"2024-08-14","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-08-02","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-08-15","defaultRemindTime":1723593600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-19","payableDate":"2024-08-15","currency":"USD","dateTimestamp":1723557600000,"payDate":"2024-09-19"},{"date":"2024-05-08","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-04-26","type":"dividend","market":"AU","newRecordDate":"2024-05-09","defaultRemindTime":1715126400000,"name":"Resmed DRC","recordDate":"2024-06-13","payableDate":"2024-05-09","currency":"USD","dateTimestamp":1715090400000,"payDate":"2024-06-13"},{"date":"2024-02-07","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-01-25","type":"dividend","market":"AU","newRecordDate":"2024-02-08","defaultRemindTime":1707260400000,"name":"Resmed DRC","recordDate":"2024-03-14","payableDate":"2024-02-08","currency":"USD","dateTimestamp":1707224400000,"payDate":"2024-03-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}]}}